$4.67
0.00% yesterday
Nasdaq, Aug 27, 10:00 pm CET
ISIN
US61225M1027
Symbol
GLUE

Monte Rosa Therapeutics Inc Stock price

$4.67
-0.88 15.86% 1M
-0.78 14.31% 6M
-2.27 32.71% YTD
-2.10 31.02% 1Y
-4.15 47.05% 3Y
-16.51 77.95% 5Y
-16.51 77.95% 10Y
-16.51 77.95% 20Y
Nasdaq, Closing price Wed, Aug 27 2025
+0.00 0.00%
ISIN
US61225M1027
Symbol
GLUE
Industry

Key metrics

Basic
Market capitalization
$288.4m
Enterprise Value
$-2.2m
Net debt
positive
Cash
$290.6m
Shares outstanding
61.7m
Valuation (TTM | estimate)
P/E
16.1 | negative
P/S
1.6 | 2.1
EV/Sales
negative | negative
EV/FCF
negative
P/B
1.1
Financial Health
Equity Ratio
50.8%
Return on Equity
-32.6%
ROCE
4.7%
ROIC
28.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$178.0m | $139.0m
EBITDA
$23.3m | $-56.1m
EBIT
$15.0m | $-58.7m
Net Income
$24.2m | $-13.4m
Free Cash Flow
$23.9m
Growth (TTM | estimate)
Revenue
2,990.1% | 83.8%
EBITDA
117.7% | 23.1%
EBIT
110.7% | 27.7%
Net Income
118.5% | 81.6%
Free Cash Flow
135.2%
Margin (TTM | estimate)
Gross
-
EBITDA
13.1% | -40.4%
EBIT
8.4%
Net
13.6% | -9.6%
Free Cash Flow
13.4%
More
EPS
$0.3
FCF per Share
$0.4
Short interest
17.9%
Employees
142
Rev per Employee
$530.0k
Show more

Is Monte Rosa Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Monte Rosa Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Monte Rosa Therapeutics Inc forecast:

13x Buy
87%
2x Hold
13%

Analyst Opinions

15 Analysts have issued a Monte Rosa Therapeutics Inc forecast:

Buy
87%
Hold
13%

Financial data from Monte Rosa Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
178 178
2,990% 2,990%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 34 34
3% 3%
19%
- Research and Development Expense 129 129
17% 17%
73%
23 23
118% 118%
13%
- Depreciation and Amortization 8.34 8.34
9% 9%
5%
EBIT (Operating Income) EBIT 15 15
111% 111%
8%
Net Profit 24 24
119% 119%
14%

In millions USD.

Don't miss a Thing! We will send you all news about Monte Rosa Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Monte Rosa Therapeutics Inc Stock News

Positive
The Motley Fool
21 days ago
Monte Rosa Therapeutics (GLUE -1.26%), a biotechnology company developing molecular glue degrader therapies, announced results for the second quarter on August 7, 2025. The standout news was a sharp jump in GAAP revenue, which reached $23.2 million, well above GAAP expectations of $7.4 million.
Neutral
GlobeNewsWire
21 days ago
Phase 1 study of NEK7-directed molecular glue degrader (MGD) MRT-8102 underway, to investigate a potential novel therapeutic approach for treating inflammatory diseases driven by the NLRP3 inflammasome; initial readout anticipated in H1 2026 VAV1-directed MGD MRT-6160 advancing toward anticipated initiation of multiple Phase 2 studies in immune-mediated diseases Phase 1/2 study of GSPT1-directe...
Neutral
GlobeNewsWire
about one month ago
MRT-8102 Phase 1 study includes single and multiple ascending dose cohorts in healthy volunteers and is designed to evaluate safety, pharmacokinetics, NEK7 protein degradation, and other key downstream pharmacodynamic markers; initial results anticipated in H1 2026 Additional Phase 1 cohort designed to evaluate potential early proof of concept in subjects with increased cardiovascular disease (...
More Monte Rosa Therapeutics Inc News

Company Profile

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Head office United States
CEO Markus Warmuth
Employees 142
Founded 2019
Website www.monterosatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today